Reassessing the Duration of Induction Therapy for Newly Diagnosed, Transplant‐Eligible Myeloma Patients in the Context of Quadruple CD38 Monoclonal Antibody‐Based Regimens: Is 24 Weeks Optimal?
Abstract
A similar theme emerges across the carfilzomib-based CD38 quads.At the end of 16 weeks of induction, the MRD negativity was 38% with DKRD and 45% with IsaKRD in the MASTER and IsKia studies, respectively [15,16].MRD negativity across the GMMG CONCEPT and IFM 2018-04, which enrolled only high-risk myeloma patients, was 41% and 68%, respectively, after 24 weeks of induction [17,18].Across these trials, there was variation in the MRD assessment method, with flow cytometry
Fields of Study & Subjects
Multiple Myeloma Research and Treatments
Monoclonal and Polyclonal Antibodies Research
Chronic Lymphocytic Leukemia Research
Publication details
- Journal / source
- American Journal of Hematology
- Volume
- 101
- Issue
- 5
- Pages
- 1141–1147
- Publication date
- 26 January 2026
- Language
- EN